BioMarin Pharmaceutical (NASDAQ:BMRN) Shares Gap Up – Still a Buy?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shares gapped up prior to trading on Friday . The stock had previously closed at $51.95, but opened at $54.80. BioMarin Pharmaceutical shares last traded at $60.7930, with a volume of 2,560,749 shares changing hands.

Key Stores Impacting BioMarin Pharmaceutical

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Strategic, revenue-accretive acquisition: BioMarin will pay ~$4.8B to buy Amicus, adding marketed drugs (Galafold for Fabry; Pombiliti + Opfolda for Pompe) and management projects the deal will accelerate revenue growth and be accretive to non‑GAAP EPS within 12 months. PR Newswire
• Positive Sentiment: Immediate revenue contribution: The acquired brands generated roughly $599M in the past four quarters, providing near-term top-line lift and diversification of BioMarin’s marketed portfolio. BioSpace
• Positive Sentiment: Patent/litigation clarity cited: Company commentary indicates resolution of pending U.S. patent litigation around Galafold will accelerate revenue post-close, reducing a key uncertainty. PR Newswire
• Positive Sentiment: Analyst / market support: Analysts are framing the deal as strategic; Wedbush maintained a Buy and $94 price target, and several outlets highlight strong investor enthusiasm. Unusual options activity — a big increase in calls — underscores bullish positioning. TipRanks
• Neutral Sentiment: Market reaction / volume and calls: Heavy trading and a surge in call buying indicate speculative and directional interest; follow-through will depend on deal close and integration updates. (No direct link)
• Neutral Sentiment: Management investor call: BioMarin held an M&A call to discuss deal rationale and timing — listen for close timing, expected synergies and integration plans. Seeking Alpha transcript
• Negative Sentiment: Cash/financing and integration risks: The all-cash $4.8B price is sizable — potential pressure on liquidity or need for financing, and integration/execution risk could weigh if synergies are slower than expected. Reuters
• Negative Sentiment: Valuation / execution risk: Investors will scrutinize the price paid vs. long-term upside — overpaying or missed sales recovery for acquired brands would reverse some of the positive reaction. WSJ

Analyst Upgrades and Downgrades

Several equities research analysts have commented on BMRN shares. Leerink Partnrs lowered shares of BioMarin Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 3rd. Tudor Pickering set a $88.00 price target on shares of BioMarin Pharmaceutical in a research report on Monday, November 3rd. HC Wainwright dropped their price objective on BioMarin Pharmaceutical from $60.00 to $55.00 and set a “neutral” rating for the company in a research note on Monday, October 27th. Leerink Partners downgraded BioMarin Pharmaceutical from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $82.00 to $60.00 in a research report on Wednesday, December 3rd. Finally, JPMorgan Chase & Co. raised their price target on BioMarin Pharmaceutical from $116.00 to $119.00 and gave the company an “overweight” rating in a research report on Thursday, October 9th. Sixteen equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, BioMarin Pharmaceutical presently has a consensus rating of “Moderate Buy” and an average price target of $88.61.

BioMarin Pharmaceutical Trading Up 17.7%

The firm has a market cap of $11.75 billion, a price-to-earnings ratio of 22.99, a price-to-earnings-growth ratio of 1.02 and a beta of 0.30. The business has a 50 day moving average of $53.67 and a 200 day moving average of $55.62. The company has a quick ratio of 3.10, a current ratio of 4.83 and a debt-to-equity ratio of 0.10.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its earnings results on Monday, October 27th. The biotechnology company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.20). BioMarin Pharmaceutical had a net margin of 16.82% and a return on equity of 9.53%. The firm had revenue of $776.13 million during the quarter, compared to analyst estimates of $782.42 million. During the same period in the previous year, the firm posted $0.91 EPS. The company’s revenue for the quarter was up 4.1% compared to the same quarter last year. BioMarin Pharmaceutical has set its FY 2025 guidance at 3.500-3.600 EPS. On average, research analysts forecast that BioMarin Pharmaceutical Inc. will post 3.15 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Brooklyn Investment Group grew its position in shares of BioMarin Pharmaceutical by 2,250.0% in the first quarter. Brooklyn Investment Group now owns 564 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 540 shares during the period. Quantbot Technologies LP increased its stake in shares of BioMarin Pharmaceutical by 220.4% during the 1st quarter. Quantbot Technologies LP now owns 8,044 shares of the biotechnology company’s stock valued at $569,000 after acquiring an additional 5,533 shares during the last quarter. Hsbc Holdings PLC lifted its holdings in shares of BioMarin Pharmaceutical by 66.7% during the 1st quarter. Hsbc Holdings PLC now owns 326,034 shares of the biotechnology company’s stock worth $23,000,000 after acquiring an additional 130,504 shares during the period. Allstate Corp boosted its position in shares of BioMarin Pharmaceutical by 49.3% in the first quarter. Allstate Corp now owns 8,352 shares of the biotechnology company’s stock worth $590,000 after acquiring an additional 2,758 shares during the last quarter. Finally, AlphaQuest LLC increased its position in BioMarin Pharmaceutical by 145.0% during the first quarter. AlphaQuest LLC now owns 25,261 shares of the biotechnology company’s stock worth $1,786,000 after purchasing an additional 14,950 shares during the last quarter. 98.71% of the stock is currently owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.